Hybrid polypeptides having glucose lowering activity
US8076288B2 · kind B2 · utility
44Cited by
34References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2005 |
| Grant date | Dec 13, 2011 |
| Priority date | — |
| Expiry date | Feb 16, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.